Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) generates frequent news as a medical technology company focused on obstructive sleep apnea (OSA), snoring and other sleep-related breathing disorders. News about Vivos often centers on its FDA-cleared oral appliance technologies, clinical data releases, acquisitions of sleep centers and collaborations with medical practices that adopt its treatment methods.
Readers following VVOS news can expect regular updates on the company’s Complete Airway Repositioning and/or Expansion (CARE) devices, including the DNA appliance for pediatric OSA and other oral appliances in its portfolio. Vivos has announced multicenter clinical trial results, additional clinical datasets and peer-reviewed publications that it says support the safety and efficacy of its devices in both children and adults. These clinical milestones are a recurring theme in the company’s press releases.
Vivos also issues news about its business model and operations, such as the acquisition of The Sleep Center of Nevada and the rollout of an updated sleep practice affiliation model with partners like MISleep Solutions in Auburn Hills, Michigan. These items describe how Vivos integrates its diagnostic tools and therapies into sleep testing and treatment centers, and how it deploys Sleep Optimization teams to manage patient demand.
In addition, VVOS news includes financial results, conference call announcements, Medicare and CMS PDAC developments related to devices like the VidaSleep oral appliance, and participation in investor or research-focused events. For investors and observers interested in the intersection of sleep medicine, medical devices and healthcare services, the VVOS news feed offers ongoing insight into how Vivos is applying its technologies and partnerships in the OSA treatment landscape.
Vivos Therapeutics, Inc. (Nasdaq: VVOS) announced the pricing of a follow-on public offering of 4,000,000 shares of its common stock at $6.00 per share, aiming for gross proceeds of $24 million before deductions. The offering includes a 45-day option for underwriters to buy an additional 600,000 shares. Roth Capital Partners is the sole book-running manager for the offering. The Securities and Exchange Commission (SEC) has declared effective registration statements, and a final prospectus will be filed with the SEC. Investors are encouraged to read the prospectus for complete information.
Vivos Therapeutics (NASDAQ: VVOS) announced the appointment of Dr. Mimi Guarneri as Medical Director of Clinical Education, effective April 1, 2021. Dr. Guarneri is a renowned Integrative Cardiologist, board-certified in multiple specialties, and a founder of The Academy of Integrative Health and Medicine. Her role will focus on promoting the Vivos Medical Integration Division, leveraging her expertise to enhance physician awareness of Vivos’ innovative treatments for obstructive sleep apnea (OSA). The company aims to improve patient outcomes with its non-invasive Vivos System, already utilized by over 1,200 dentists worldwide.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will present at the Emerging Growth Conference on April 14, 2021, at 9:00 am EDT. The presentation will be led by CEO Kirk Huntsman, CFO Brad Amman, and Investor Relations Officer Ed Loew.
Investors can register for a free spectator pass. Vivos specializes in treatments for sleep-disordered breathing, particularly mild-to-moderate obstructive sleep apnea (OSA), offering the innovative Vivos System, which is a non-invasive solution already benefiting over 15,000 patients worldwide.
Vivos Therapeutics (NASDAQ: VVOS) has announced the launch of MyoCorrect, a telemedicine service offering orofacial myofunctional therapy (OMT) to enhance the treatment of obstructive sleep apnea (OSA). This initiative aims to provide Vivos-trained providers with greater access to OMT, expected to drive additional revenue through increased Vivos System cases and service fees. Vivos anticipates that MyoCorrect will strengthen its competitive positioning in the OSA market, as trained dentists report numerous benefits from integrating OMT into their treatment protocols.
Vivos Therapeutics reported a 15% revenue increase for full year 2020, reaching $13.1 million, up from $11.4 million in 2019. The fourth quarter revenue hit $3.3 million with a gross profit of $2.7 million, marking an 81% gross margin. Despite a net loss of $12.1 million for the full year, the company surpassed 15,000 cases treated. Financial resilience was aided by a $21.6 million IPO in December 2020. New product launches, including AireO2 and VivoScore, are expected to enhance their market position.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will present at the Benzinga Biotech Small Cap Conference on March 25, 2021, at 11:40 am Eastern Time. The conference runs from March 24-25, 2021. Key presenters include CEO Kirk Huntsman, CFO Brad Amman, and Investor Relations Officer Ed Loew. Vivos focuses on innovative treatments for sleep-disordered breathing, particularly mild-to-moderate obstructive sleep apnea (OSA), using non-invasive methods. Interested investors can register for a free spectator pass via the provided link.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced plans to release its financial results for Q4 and the full year ended December 31, 2020, after market close on March 25, 2021. The company will hold a conference call at 5:00 p.m. ET to discuss the results and its growth strategy. Vivos aims to provide innovative treatments for sleep-disordered breathing, specifically mild-to-moderate obstructive sleep apnea (OSA), with its Vivos System oral appliances, proven effective in over 15,000 patients. The company is committed to growth through improved treatment technologies.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will present at the Q1 Virtual Investor Summit on March 23, 2021, at 1:30 PM ET. Key executives, including CEO Kirk Huntsman and CFO Brad Amman, will discuss the company's focus on innovative treatments for sleep-disordered breathing, particularly obstructive sleep apnea (OSA). The Vivos System offers a non-invasive, personalized therapy for patients, which has successfully treated over 15,000 patients globally. Interested investors can register for the presentation and access a replay afterward on Vivos' website.
Vivos Therapeutics (NASDAQ: VVOS) announced the opening of its first Pneusomnia clinic in Del Mar, California, aimed at addressing sleep apnea through the Vivos System. This integrated medical-dental center, led by Dr. Mimi Guarneri, will provide innovative, non-invasive treatments for mild-to-moderate obstructive sleep apnea (OSA). The Vivos System is designed to treat the root causes of sleep apnea without requiring lifelong intervention. Additional clinics are planned across the U.S., enhancing patient access to vital screenings and treatments.
Vivos Therapeutics (NASDAQ: VVOS) announced its participation in the 33rd Annual ROTH Conference from March 15-17, 2021. CEO Kirk Huntsman, CFO Brad Amman, and Investor Relations Officer Ed Loew will present on March 16 at 11:30 am ET. Investors can register for the presentation through a provided link and a replay will be available on the company's website. Vivos specializes in innovative treatments for sleep-disordered breathing, particularly mild to moderate obstructive sleep apnea, using its Vivos System that has helped over 18,000 patients globally.
FAQ
What is the current stock price of Vivos Therapeutics (VVOS)?
What is the market cap of Vivos Therapeutics (VVOS)?
